MEDPACE HOLDINGS INC (MEDP) Fundamental Analysis & Valuation

NASDAQ:MEDP • US58506Q1094

Current stock price

508.52 USD
+12.52 (+2.52%)
At close:
510 USD
+1.48 (+0.29%)
After Hours:

This MEDP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. MEDP Profitability Analysis

1.1 Basic Checks

  • MEDP had positive earnings in the past year.
  • MEDP had a positive operating cash flow in the past year.
  • In the past 5 years MEDP has always been profitable.
  • Each year in the past 5 years MEDP had a positive operating cash flow.
MEDP Yearly Net Income VS EBIT VS OCF VS FCFMEDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • The Return On Assets of MEDP (22.84%) is better than 98.25% of its industry peers.
  • The Return On Equity of MEDP (98.27%) is better than 100.00% of its industry peers.
  • MEDP has a Return On Invested Capital of 71.19%. This is amongst the best in the industry. MEDP outperforms 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 11.38%.
  • The 3 year average ROIC (49.20%) for MEDP is below the current ROIC(71.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.84%
ROE 98.27%
ROIC 71.19%
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
MEDP Yearly ROA, ROE, ROICMEDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • Looking at the Profit Margin, with a value of 17.83%, MEDP belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
  • In the last couple of years the Profit Margin of MEDP has grown nicely.
  • MEDP's Operating Margin of 21.14% is amongst the best of the industry. MEDP outperforms 89.47% of its industry peers.
  • In the last couple of years the Operating Margin of MEDP has grown nicely.
  • MEDP has a worse Gross Margin (30.06%) than 73.68% of its industry peers.
  • MEDP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.14%
PM (TTM) 17.83%
GM 30.06%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
MEDP Yearly Profit, Operating, Gross MarginsMEDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MEDP Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDP is creating value.
  • Compared to 1 year ago, MEDP has less shares outstanding
  • Compared to 5 years ago, MEDP has less shares outstanding
  • There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MEDP Yearly Shares OutstandingMEDP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
MEDP Yearly Total Debt VS Total AssetsMEDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • MEDP has an Altman-Z score of 7.34. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
  • MEDP has a better Altman-Z score (7.34) than 89.47% of its industry peers.
  • MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.34
ROIC/WACC6.51
WACC10.93%
MEDP Yearly LT Debt VS Equity VS FCFMEDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 0.74 indicates that MEDP may have some problems paying its short term obligations.
  • The Current ratio of MEDP (0.74) is worse than 94.74% of its industry peers.
  • A Quick Ratio of 0.74 indicates that MEDP may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.74, MEDP is not doing good in the industry: 94.74% of the companies in the same industry are doing better.
  • The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.74
MEDP Yearly Current Assets VS Current LiabilitesMEDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. MEDP Growth Analysis

3.1 Past

  • MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.14%, which is quite impressive.
  • MEDP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 31.30% yearly.
  • The Revenue has grown by 19.97% in the past year. This is quite good.
  • MEDP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.27% yearly.
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%

3.2 Future

  • MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.52% yearly.
  • MEDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.03% yearly.
EPS Next Y13.94%
EPS Next 2Y12.47%
EPS Next 3Y12.37%
EPS Next 5Y10.52%
Revenue Next Year11.83%
Revenue Next 2Y9.77%
Revenue Next 3Y9.63%
Revenue Next 5Y9.03%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MEDP Yearly Revenue VS EstimatesMEDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
MEDP Yearly EPS VS EstimatesMEDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

4

4. MEDP Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 33.24, MEDP can be considered very expensive at the moment.
  • 64.91% of the companies in the same industry are more expensive than MEDP, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.21. MEDP is valued slightly more expensive when compared to this.
  • A Price/Forward Earnings ratio of 29.17 indicates a quite expensive valuation of MEDP.
  • Based on the Price/Forward Earnings ratio, MEDP is valued a bit cheaper than 63.16% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.10, MEDP is valued a bit more expensive.
Industry RankSector Rank
PE 33.24
Fwd PE 29.17
MEDP Price Earnings VS Forward Price EarningsMEDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 64.91% of the companies in the same industry are more expensive than MEDP, based on the Enterprise Value to EBITDA ratio.
  • 78.95% of the companies in the same industry are more expensive than MEDP, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 21.17
EV/EBITDA 24.75
MEDP Per share dataMEDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of MEDP may justify a higher PE ratio.
  • A more expensive valuation may be justified as MEDP's earnings are expected to grow with 12.37% in the coming years.
PEG (NY)2.38
PEG (5Y)1.06
EPS Next 2Y12.47%
EPS Next 3Y12.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MEDP Dividend Analysis

5.1 Amount

  • No dividends for MEDP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDP Fundamentals: All Metrics, Ratios and Statistics

MEDPACE HOLDINGS INC

NASDAQ:MEDP (4/7/2026, 8:50:25 PM)

After market: 510 +1.48 (+0.29%)

508.52

+12.52 (+2.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-09
Earnings (Next)04-22
Inst Owners84.9%
Inst Owner Change0%
Ins Owners0.51%
Ins Owner Change-4.93%
Market Cap14.43B
Revenue(TTM)2.53B
Net Income(TTM)451.12M
Analysts72
Price Target500.23 (-1.63%)
Short Float %6.13%
Short Ratio3.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.54%
Min EPS beat(2)7.52%
Max EPS beat(2)9.56%
EPS beat(4)4
Avg EPS beat(4)9.37%
Min EPS beat(4)2.57%
Max EPS beat(4)17.84%
EPS beat(8)8
Avg EPS beat(8)12.36%
EPS beat(12)11
Avg EPS beat(12)11.35%
EPS beat(16)15
Avg EPS beat(16)14.34%
Revenue beat(2)2
Avg Revenue beat(2)0.84%
Min Revenue beat(2)0.75%
Max Revenue beat(2)0.93%
Revenue beat(4)4
Avg Revenue beat(4)3.88%
Min Revenue beat(4)0.75%
Max Revenue beat(4)9.78%
Revenue beat(8)4
Avg Revenue beat(8)0.78%
Revenue beat(12)7
Avg Revenue beat(12)1.31%
Revenue beat(16)10
Avg Revenue beat(16)1.28%
PT rev (1m)0.56%
PT rev (3m)-9.13%
EPS NQ rev (1m)-0.41%
EPS NQ rev (3m)0.99%
EPS NY rev (1m)0%
EPS NY rev (3m)3.69%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-0.14%
Valuation
Industry RankSector Rank
PE 33.24
Fwd PE 29.17
P/S 5.7
P/FCF 21.17
P/OCF 20.23
P/B 31.44
P/tB N/A
EV/EBITDA 24.75
EPS(TTM)15.3
EY3.01%
EPS(NY)17.43
Fwd EY3.43%
FCF(TTM)24.03
FCFY4.72%
OCF(TTM)25.13
OCFY4.94%
SpS89.16
BVpS16.18
TBVpS-8.34
PEG (NY)2.38
PEG (5Y)1.06
Graham Number74.62
Profitability
Industry RankSector Rank
ROA 22.84%
ROE 98.27%
ROCE 84.68%
ROIC 71.19%
ROICexc 333.94%
ROICexgc N/A
OM 21.14%
PM (TTM) 17.83%
GM 30.06%
FCFM 26.95%
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
ROICexc(3y)169.04%
ROICexc(5y)114.84%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)58.52%
ROCE(5y)48.87%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y101.11%
ROICexc growth 5Y74.12%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
F-Score7
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 111.49%
Cap/Sales 1.24%
Interest Coverage 250
Cash Conversion 126.67%
Profit Quality 151.15%
Current Ratio 0.74
Quick Ratio 0.74
Altman-Z 7.34
F-Score7
WACC10.93%
ROIC/WACC6.51
Cap/Depr(3y)125.21%
Cap/Depr(5y)134.9%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.98%
Profit Quality(3y)144.35%
Profit Quality(5y)141.17%
High Growth Momentum
Growth
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
EPS Next Y13.94%
EPS Next 2Y12.47%
EPS Next 3Y12.37%
EPS Next 5Y10.52%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%
Revenue Next Year11.83%
Revenue Next 2Y9.77%
Revenue Next 3Y9.63%
Revenue Next 5Y9.03%
EBIT growth 1Y19.71%
EBIT growth 3Y24.28%
EBIT growth 5Y26.22%
EBIT Next Year16.28%
EBIT Next 3Y12.32%
EBIT Next 5Y10.93%
FCF growth 1Y19.15%
FCF growth 3Y24.75%
FCF growth 5Y24.56%
OCF growth 1Y17.15%
OCF growth 3Y22.49%
OCF growth 5Y22.49%

MEDPACE HOLDINGS INC / MEDP Fundamental Analysis FAQ

What is the fundamental rating for MEDP stock?

ChartMill assigns a fundamental rating of 7 / 10 to MEDP.


Can you provide the valuation status for MEDPACE HOLDINGS INC?

ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.


Can you provide the profitability details for MEDPACE HOLDINGS INC?

MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.


What is the earnings growth outlook for MEDPACE HOLDINGS INC?

The Earnings per Share (EPS) of MEDPACE HOLDINGS INC (MEDP) is expected to grow by 13.94% in the next year.